Ghidurile ESC - Media Med Publicis

Ghiduri ale Societatii Europene de Cardiologie
350. Bartecchi CE, MacKenzie TD, Schrier RW. The human costs of tobacco
use (1). N Engl J Med 1994;330:907-912.
351. MacKenzie TD, Bartecchi CE, Schrier RW. The human costs of tobacco
use (2). N Engl J Med 1994;330:975-980.
352. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: impli
cations for nicotine replacement therapy. J Am Coll Cardiol
1997;29:1422-1431.
353. Tzivoni D, Keren A, Meyler S, Khoury Z, Lerer T, Brunel P. Cardiovascular
safety of transdermal nicotine patches in patients with coronary artery
disease who try to quit smoking. Cardiovasc Drugs Ther 1998; 12:
239-244.
354. Working Group for the Study of Transdermal Nicotine in Patients with
Coronary artery disease. Nicotine replacement therapy for patients
with coronary artery disease. Arch Intern Med 1994; 154:989-995.
355. Critchley J, Capewell S. Smoking cessation for the secondary prevention
of coronary heart disease. Cochrane Database Syst Rev 2003, Issue 4.
Art. No.: CD003041, doi: 10.1002/14651858.CD003041.pub2.
356. Smith GD, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol concen
tration and mortality. The Whitehall Study. JAMA 1992;267:70-76.
357. Doll R, Peto R, Hall E, Wheatley K, Gray R. Alcohol and coronary heart
disease reduction among British doctors: confounding or causality?
Eur Heart J 1997;18:23-25.
358. Di Castelnuovo A, Rotondo S, Iacoviello L, Donati MB, De Gaetano G.
Meta-analysis of wine and beer consumption in relation to vascular
risk. Circulation 2002; 105:2836-2844.
359. Sesso HD, Stampfer MJ, Rosner B, Hennekens CH, Manson JE, Gaziano JM.
7 year changes in alcohol consumption and subsequent risk of cardiovas
cular disease in men. Arch Intern Med 2000; 160:2605-2612.
360. Goldberg IJ, Mosca L, Piano MR, Fisher EA. AHA Science Advisory: Wine
and your heart: a science advisory for healthcare professionals from the
Nutrition Committee, Council on Epidemiology and Prevention, and
Council on Cardiovascular Nursing of the American Heart Association.
Circulation 2001;103:472-475.
361. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.
Dietary supplementation with n-3 polyunsaturated fatty acids
and vitamin E after myocardial infarction: results of the GISSI-
Prevenzione trial. Lancet 1999;354:447-455.
362. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R et al.
Early protection against sudden death by n-3 polyunsaturated fatty
acids after myocardial infarction: time-course analysis of the results
of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto
Miocardico (GISSI)-Prevenzione. Circulation 2002; 105:1897-1903.
363. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty
acids in coronary heart disease: a meta-analysis of randomized con
trolled trials. Am JMed2002;112:298-304.
364. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of differ
ent antilipidemic agents and diets on mortality: a systematic review.
Arch Intern Med 2005; 165:725-730.
365. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil,
omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb
Vasc Biol 2003;23:e20-e30.
366. He K, Song Y, Daviglus ML, Liu K, Van Horn L, Dyer AR et al. Accumulated
evidence on fish consumption and coronary heart disease mortality: a
meta-analysis of cohort studies. Circulation 2004;109:2705-2711.
367. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection
Study of antioxidant vitamin supplementation in 20,536 high-risk indi
viduals: a randomised placebo-controlled trial. Lancet 2002;360:23-33.
368. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplemen
tation and cardiovascular events in high-risk patients. The Heart
Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;
342:154-160.
369. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witztum JL.
Antioxidant vitamin supplements and cardiovascular disease.
Circulation 2004; 110:637-641.
370. American Diabetes Association. Standards of medical care for patients
with diabetes mellitus. Diabetes Care 2003;26(Suppl. 1):s33-s50.
371. Inzucchi SE, Amatruda JM. Lipid management in patients with diabetes:
translating guidelines into action. Diabetes Care 2003;26:1309-1311.
372. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O.
Multifactorial intervention and cardiovascular disease in patients with
type 2 diabetes. N Engl J Med 2003;348:383-393.
373. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M,
Moules IK et al. Secondary prevention of macrovascular events in
patients with type 2 diabetes in the PROactive Study (PROspective
pioglitAzone Clinical Trial In macroVascular Events): a randomised
controlled trial. Lancet 2005;366:1279-1289.
374. Lewin B, Cay E, Todd I, Goodfield N, Bloomfield P, Elton R. The angina
management programme: a rehabiliatation treatment. Br J Cardiol
1995;2:221-226.
375. Lewin RJ, Furze G, Robinson J, Griffith K, Wiseman S, Pye M et al. A ran
domised controlled trial of a self-management plan for patients with
newly diagnosed angina. Br J Gen Pract 2002;52:194-6-199-201.
376. Fox KM, Thadani U, Ma PT, Nash SD, Keating Z, Czorniak MA et al.
Sildenafil citrate does not reduce exercise tolerance in men with erec
tile dysfunction and chronic stable angina. Eur Heart J 2003; 24:
2206-2212.
377. Kerins DM. Drugs used for the treatment of myocardial ischaemia.
Goodman & Gilmans The Pharmacological Basis of Therapeutics.
10th ed. McGraw-Hill; 2001.
378. Mittleman MA, Glasser DB, Orazem J. Clinical trials of sildenafil citrate
(Viagra) demonstrate no increase in risk of myocardial infarction and
cardiovascular death compared with placebo. Int J Clin Pract
2003;57:597-600.
379. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS
et al. ACC/AHA 2002 guideline update for the management of patients
with chronic stable angina-summary article: a report of the American
College of Cardiology/American Heart Association Task Force on prac
tice guidelines (Committee on the Management of Patients With
Chronic Stable Angina). J Am Coll Cardiol 2003;41:159-168.
380. Luscher TF. Treatment of stable angina. Use drugs before percutaneous
transluminal coronary angioplasty. BMJ 2000;321:62-63.
381. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus
conservative therapy in nonacute coronary artery disease: a
meta-analysis. Circulation 2005; 111:2906-2912.
382. Hueb W, Soares PR, Gersh BJ, Cesar LA, Luz PL, Puig LB et al. The medi
cine, angioplasty, or surgery study (MASS-II): a randomized, controlled
clinical trial of three therapeutic strategies for multivessel coronary
artery disease: 1 year results. J Am Coll Cardiol 2004;43:1743-1751.
383. Antiplatelet Trialists' Collaboration. Collaborative overview of random
ised trials of antiplatelet therapy-I: Prevention of death, myocardial
infarction, and stroke by prolonged antiplatelet therapy in various
categories of patients. BMJ 1994;308:81-106.
384. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B
et al. Expert consensus document on the use of antiplatelet agents. The
task force on the use of antiplatelet agents in patients with athero
sclerotic cardiovascular disease of the European society of cardiology.
Eur Heart J 2004; 25:166-181.
385. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active
drugs: the relationships among dose, effectiveness, and side effects:
the Seventh ACCP Conference on Antithrombotic and Thrombolytic
Therapy. Chest 2004; 126(Suppl. 3):234S-264S.
386. Patrono С Aspirin resistance: definition, mechanisms and clinical read
outs. J Thromb Haemost 2003;1:1710-1713.
387. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of
randomised trials of antiplatelet therapy for prevention of death, myo
cardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
388. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL et al. Effects
of aspirin dose when used alone or in combination with clopidogrel in
patients with acute coronary syndromes: observations from the
Clopidogrel in Unstable angina to prevent Recurrent Events (CURE)
study. Circulation 2003;108:1682-1687.
389. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M et al.
Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ
1995;310:827-830.
390. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term
use of aspirin: meta-analysis. BMJ 2000;321:1183-1187.
391. Sudlow C, Baigent С The adverse effects of different doses of aspirin:
a systematic review of randomised trials and observational studies.
(Abstract). Stroke 2000;31:2869.
392. Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose
aspirin therapy for chronic stable angina. A randomized, placebocontrolled
clinical trial. Ann Intern Med 1991;114:835-839.
393. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med
2004;351:1709-1711.
394. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K
et al. Cardiovascular events associated with rofecoxib in a colorectal
adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102.
395. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of
cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet
2004;364:2021-2029.
396. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardio
vascular risk. Circulation 2005; 112:759-770.
397. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P et al.
Cardiovascular risk associated with celecoxib in a clinical trial for color
59